Pollen Allergy Clinical Trial
Official title:
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
| Verified date | March 2024 |
| Source | Mabylon AG |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.
| Status | Enrolling by invitation |
| Enrollment | 300 |
| Est. completion date | December 31, 2025 |
| Est. primary completion date | December 31, 2025 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens - Male or female patients older than 18 years - Written informed consent for providing blood and also to allow experimental manipulation Exclusion Criteria: - Age < 18 years - Any corticosteroids within the last three days - Oral corticosteroid therapy within the last ten days - Parenteral depot corticosteroids within the last three months |
| Country | Name | City | State |
|---|---|---|---|
| Switzerland | Immunologie Zentrum Zürich | Zürich |
| Lead Sponsor | Collaborator |
|---|---|
| Mabylon AG |
Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Antibody profiling | Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients. | October 2018 - September 2021 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01500642 -
Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy
|
Phase 3 | |
| Completed |
NCT00263627 -
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
|
Phase 3 | |
| Terminated |
NCT04874714 -
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT04622917 -
Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.
|
Phase 4 |